Specialty Pharmacy

Lilly Study Reveals Less than 30% of People Living with Migraine Take Recommended Prescription Medications

INDIANAPOLIS, June 16, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that less than 30 percent of people with migraine are taking a recommended prescription medication, highlighting the need for improvement in migraine care. These data are from the initial cohort of the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study, which …

Read More »

Inventiva’s Lanifibranor Meets Primary and Key Secondary Endpoints in Phase IIb Trial in Non-Alcoholic Steatohepatitis

Daix (France), June 15, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced positive topline results from the Phase IIb NATIVE (NAsh Trial to Validate IVA337 Efficacy) …

Read More »

Pfizer Announces Positive Top-Line Results from a Phase 3 Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 to <18 years of age with moderate to severe atopic dermatitis (AD) who were also on background topical …

Read More »

FDA Approves Lilly’s Tauvid for Injection for Use in Patients Being Evaluated for Alzheimer’s Disease

INDIANAPOLIS, May 28, 2020 /PRNewswire/ — TAUVID™, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).1 A neuropathological …

Read More »

Ironwood and AbbVie to Halt Development of MD-7246 After Drug Fails to Meet Endpoints in Phase 2 Trial in Patients with Abdominal Pain Associated with IBS-D

BOSTON–(BUSINESS WIRE)–Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced top-line data from a Phase II trial evaluating MD-7246 in adult patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D). The Phase II trial did not meet its primary or key secondary endpoints. Based on these …

Read More »

FDA Approves Dupixent as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis

PARIS and TARRYTOWN, N.Y. – May 26, 2020 – The U.S. Food and Drug Administration (FDA)  approved Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent is the only biologic …

Read More »

Part A of Phase 3 Trial of Dupixent for Treatment of Eosinophilic Esophagitis Meets Co-Primary Endpoints

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). The trial met both of its co-primary endpoints, as well as all key secondary endpoints. Dupixent is the first …

Read More »

Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer’s Disease

INDIANAPOLIS, May 19, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment (MCI), mild dementia (MILD), and caring for someone with Alzheimer’s disease (AD). The study, published today in The Journal of Alzheimer’s Disease, …

Read More »

Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study Showing Multifactorial Activity in Adults with NAFLD

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced positive top-line data from AXA1125-003. AXA1125-003 is a placebo-controlled, randomized, multi-arm clinical study assessing the impact of AXA1125 and AXA1957 on …

Read More »

Newron Terminates Program After Pivotal Trial of Sarizotan Fails to Meet Primary or Secondary Efficacy Variables in Patients with Rett Syndrome

MILAN & MORRISTOWN, N.J.–(BUSINESS WIRE)–Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced today that top-line results from its STARS clinical study evaluating sarizotan in patients with Rett syndrome …

Read More »